| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
GridAI Technologies Corp.$4.6
-0.26 (-5.35%)
Market Cap
30.01 M
EPS
-3.00
P/E Ratio
-
Value Trade
586.18 K
SEC Financials
Q1 2026Dilution Risk
Revenue
38.21 K
R&D Expenses
631.38 K
Operating CF
-1.79 M
Total Assets
47.97 M
Total Liabilities
20.47 M
Equity
23.60 M
D/E Ratio
12,345
27.37 %
Week
94.38 %
1 Month
79.26 %
3 Month
97.55 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
385.54 K
Monthly Burn
596.00 K
Runway
0 mo
Burn Trend
SEC Filing
May 27, 2026
Overview
Volume
16.59 K
52 Week Range
1.65 - 7.02
% held by Insiders
8.38 %
% held by Institutions
5.24 %
Enterprise Value
40.29 M
Total Shares
3.36 M
Short %
2.39 %
Float Shares
3.07 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GRDX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GridAI Technologies Corp. (GRDX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
GRDX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GRDX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GRDX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GRDX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
GRDX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GRDXGridAI Technologies Corp. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
GridAI Technologies Corp. announced that it received a notice from Nasdaq regarding its late Form 10-K filing, indicating non-compliance with requirements for continued listing. The company must submit a plan to regain compliance by June 22, 2026. If accepted, Nasdaq may grant an extension of up to 180 days. However, there are no guarantees that the plan will be accepted, raising concerns about future compliance.
Read more →GRDXEric Corbett 100 Long Branch Avenue Unit 21 Etobicoke, Ontario, M8W 0C1 CANADA Via Email (jason@accessalternative.com; edborkowski@gmail.com)
Eric Corbett has announced his resignation from the Board of Directors of Entero Therapeutics Inc., effective November 28, 2025. The resignation stems from fundamental disagreements with the management and the Board's policies and practices. This internal conflict may raise concerns regarding the company's governance and future strategic decisions.
Read more →GRDXENTERO THERAPEUTICS (NASDAQ: ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand Transaction positions ENTO in the high-growth AI energy-infrastructure market, amid a surge of multi-b
Entero Therapeutics, Inc. (NASDAQ: ENTO) has acquired GRID AI Corp, a grid-edge AI platform, in a strategic move to enhance its position in the burgeoning AI-driven energy infrastructure market. This acquisition is expected to allow ENTO to effectively address the rising electricity demand from data centers, projected to surge significantly in the coming years. GRID AI's platform aims to facilitate dynamic load management and improve grid reliability by integrating flexible demand from various energy resources. Following regulatory approval, GRID AI will operate as a wholly owned subsidiary of ENTO, enabling expansion into new energy capacities and market opportunities.
Read more →GRDXEntero Therapeutics, Inc. Announces Reverse Stock Split
Entero Therapeutics, Inc. has announced a 1 for 3 reverse stock split to comply with Nasdaq's listing requirements, effective August 18, 2025. This split aims to address the minimum bid price requirement and reduce the outstanding shares from approximately 4.77 million to about 1.59 million. Interim CEO Richard Paolone emphasized the importance of the Nasdaq listing for enhancing shareholder value. No fractional shares will be issued, with affected shareholders receiving cash instead.
Read more →GRDXEntero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules
Entero Therapeutics, Inc. has announced a private placement of approximately $3 million with institutional investors, priced at market under Nasdaq rules. The transaction involves the sale of pre-funded and common warrants, providing significant flexibility for investors. The proceeds are intended for general corporate purposes and working capital. The expected closing date for the transaction is August 11, 2025, pending customary closing conditions. This offering reflects Entero's ongoing efforts to support its development of targeted therapies for gastrointestinal diseases.
Read more →GRDXEntero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX
Entero Therapeutics announced the signing of a rescission agreement with ImmunogenX to unwind a previously closed business combination. This decision, made after an internal review, is viewed as a strategic move to strengthen Entero's balance sheet and focus on long-term success. Furthermore, the company appointed Anna Skowron as its new Chief Financial Officer, bringing valuable experience in financial reporting and corporate governance. However, the agreement is contingent on obtaining shareholder approval by June 30, 2025.
Read more →GRDXEntero Therapeutics Appoints Richard Paolone as
Entero Therapeutics, Inc. has appointed Richard Paolone as interim CEO, bringing a wealth of experience in corporate finance, securities law, and mergers and acquisitions. Paolone is expected to leverage his expertise to guide the company in a competitive market. Entero specializes in developing targeted therapies for gastrointestinal diseases, with drugs in its pipeline aimed at significant unmet medical needs.
Read more →GRDXEntero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company Proposed merger to create N
Entero Therapeutics has announced a proposed reverse merger with Journey Therapeutics, a clinical-stage biopharmaceutical company specializing in nano-immunoconjugates for cancer treatment. Following the merger, shareholders of Journey will control 99% of the combined entity, which will operate under the Journey Therapeutics name. The merger aims to enhance Entero's existing clinical assets while advancing Journey's novel therapies targeting difficult cancers. However, the merger is subject to various conditions, including financing and regulatory approvals.
Read more →GRDXEntero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings Entero Therapeutics to integrate applications in plann
Entero Therapeutics has signed a Letter of Intent with Data Vault Holdings to license and commercialize innovative clinical trial management technologies, including QOLPOM and FotoDigm. This partnership aims to enhance compliance in clinical trials, starting with a Phase 3 trial for latiglutenase in celiac disease. The transaction hinges on securing a strategic investment which would provide significant capital and support for technology development. Should the technologies prove effective in trials, they could lead to broader applications in the pharmaceutical sector.
Read more →GRDXEntero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
Entero Therapeutics, Inc. announced it received a notification from Nasdaq regarding its failure to file the Quarterly Report on Form 10-Q for the fiscal quarter that ended June 30, 2024. The company has until October 21, 2024, to submit a compliance plan to Nasdaq, which may extend the deadline for filing up to February 17, 2025, if approved. Alongside this, Entero Therapeutics is in the process of retaining a new independent registered public accounting firm after its previous firm resigned. However, there remains uncertainty regarding the company's ability to meet Nasdaq's compliance criteria.
Read more →GRDXEntero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program
Entero Therapeutics' Chairman and CEO James Sapirstein provided a business update focusing on the development of latiglutenase, a treatment for celiac disease. The company aims to advance latiglutenase into a pivotal Phase 3 trial by 2025 and is adjusting its trial design based on previous discussions with the FDA. Entero has secured $1.9 million in financing and has streamlined its operations to support this process. Their approach reflects a strong commitment to meeting the treatment needs for patients with celiac disease.
Read more →GRDXEntero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds
Entero Therapeutics, Inc. announced the exercise of existing warrants and issuance of new ones in a private placement, resulting in approximately $1.9 million in gross proceeds. The existing warrants, totaling 1,762,674 shares, will be exercised at a reduced price of $1.09 per share. In exchange, the holders will receive new warrants for an additional 3,525,348 shares at the same exercise price, pending stockholder approval. This strategy aims to strengthen Entero's financial capabilities to further develop its innovative therapies for gastrointestinal diseases.
Read more →GRDXFirst Wave BioPharma Changes Name to Entero Therapeutics Rebranding introduced as Company advances toward Phase 3 clinical trial with lead asset - latiglutenase for the treatment of celiac disease New Nasdaq new ticker s
First Wave BioPharma has changed its name to Entero Therapeutics as it prepares for a Phase 3 clinical trial of its lead asset, latiglutenase, aimed at treating celiac disease. The rebranding reflects the company's commitment to addressing unmet gastrointestinal health needs. The new ticker symbol ENTO will be effective on May 17, 2024. Additionally, Entero is collaborating with Celiac Journey to promote awareness about celiac disease during Celiac Awareness Month. The success of the Phase 3 trial and the integration of ImmunogenX assets presents both opportunities and challenges for Entero's future.
Read more →GRDXFirst Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market
First Wave BioPharma, Inc. has announced a definitive securities purchase agreement to raise approximately $1.1 million through the sale of 366,000 shares priced at $2.95 each. Additionally, the agreement includes warrants for purchasing another 732,000 shares at an exercise price of $2.70. The proceeds from this offering will be utilized for general corporate purposes and working capital. Roth Capital Partners is acting as the exclusive placement agent for this transaction, which is expected to close around May 14, 2024.
Read more →GRDXFirst Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference Poster presentations to highlight new quantitative and serologic diagn
First Wave BioPharma announced that two research abstracts on celiac disease have been accepted for presentation at the 2024 Digestive Disease Week Conference. These presentations will focus on new diagnostic methods, including the VCIEL scale for measuring mucosal health and the dynamics of serologic changes in patients. The findings are expected to contribute significantly to the understanding and management of celiac disease, highlighting advancements in gastroenterology. The conference will take place from May 18-21, 2024, in Washington, D.C.
Read more →GRDXFirst Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline Latiglutenase is a potentially first-in-class oral biot
First Wave BioPharma has successfully completed its acquisition of ImmunogenX, integrating latiglutenase into its pipeline as a Phase 3-ready treatment for celiac disease. The merger aims to enhance First Wave's capabilities in developing targeted therapies for gastrointestinal diseases. Latiglutenase has shown promising results in earlier trials and is expected to enter Phase 3 trials in early 2025, following FDA approval of its clinical development plan. The company plans to license commercial rights for the drug to a global pharmaceutical partner and seeks additional financing to support its development efforts.
Read more →GRDXFirst Wave BioPharma, Inc. to raise approximately $4.0 million of Gross Proceeds in Registered Direct Offering
First Wave BioPharma, Inc. has announced a registered direct offering, aiming to raise approximately $4.0 million by selling 525,625 shares of common stock at a price of $7.61 per share. Alongside this, the company will issue warrants to purchase up to the same number of shares at an exercise price of $7.48 per share. The gross proceeds from the offering are designated for working capital and general corporate needs. Roth Capital Partners is acting as the exclusive placement agent, with the closing expected around March 6, 2024, pending customary conditions.
Read more →GRDXFirst Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024 Multiple clinical and development milestones anticipated in 2024, including initiation of Phase
First Wave BioPharma's Chairman and CEO, James Sapirstein, issued a letter to shareholders outlining recent achievements and the company's 2024 outlook. Key highlights include a potential merger with ImmunogenX, which would provide access to the Phase 3-ready latiglutenase for celiac disease. The company anticipates major clinical and development milestones in 2024, alongside strategic investments for commercial rights. First Wave aims to strengthen its late-stage clinical pipeline focused on gastrointestinal disorders.
Read more →GRDXFirst Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced
First Wave BioPharma has announced an agreement to exercise existing warrants and issue new ones, resulting in approximately $4.8 million in gross proceeds. The existing warrants will be exercised at a reduced price of $5.50 per share, allowing these holders to acquire new warrants at an exercise price of $5.00. The new warrants, if exercised, could yield a further 1,762,674 shares and have a five-year term. This action was structured as an at-market transaction under Nasdaq rules, involving oversight from the company's financial advisor.
Read more →GRDXFirst Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 L
First Wave BioPharma has announced its intention to streamline its clinical pipeline by entering a non-binding term sheet for the sale of its Niclosamide program, which targets inflammatory bowel diseases. This strategic decision will allow the company to focus its efforts on advancing three key late-stage clinical programs, including a Phase 3-ready treatment for celiac disease and other GI-focused therapies. The transaction is expected to close in the first half of 2024, pending various regulatory approvals and financing conditions. The sale aims to infuse the company with additional capital to bolster its development resources.
Read more →GRDXFirst Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company Phase 3-ready latiglutenase, a targeted oral biotherape
First Wave BioPharma has entered into a non-binding term sheet for a business combination with ImmunogenX, which focuses on the development of latiglutenase, a Phase 3-ready oral biotherapeutic for celiac disease. Following the transaction, First Wave aims to advance several late-stage clinical assets, enhancing its gastrointestinal disease pipeline. The completion of this merger is subject to regulatory approvals and is expected in the first half of 2024. First Wave anticipates that this strategic move will position them to capture significant market opportunities in celiac disease treatment.
Read more →GRDXFirst Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders
First Wave BioPharma announced the approval of a 1-for-20 reverse stock split by its Board of Directors, set to take effect on December 18, 2023. This decision follows the company’s special meeting of stockholders where all key proposals were approved, emphasizing corporate actions for compliance with Nasdaq's listing standards. The stock will begin trading under this new split-adjusted basis post-effective date, reducing the outstanding shares significantly. First Wave continues to advance its pipeline of therapies aimed at gastrointestinal diseases.
Read more →GRDXFirst Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.0 Million Gross Proceeds Priced At-the-Market
First Wave BioPharma announced the exercise of warrants and issuance of new warrants in a private placement, generating approximately $4 million in gross proceeds. The existing warrants were exercised at a reduced price of $0.43 per share. In place of these, new warrants for additional shares at the same price will be issued, with an exercise term of five years. This strategic move aims to financially bolster the company's growth trajectory in developing therapies for gastrointestinal diseases.
Read more →GRDXFirst Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi First Wave to develop and repurpose Capeserod for gastrointestinal (GI) indications based on AI-empowered analyses, expanding th
First Wave BioPharma has secured an exclusive global license for Capeserod from Sanofi, aiming to repurpose the drug for gastrointestinal (GI) indications. The agreement includes an upfront payment, milestone payments, and royalties on sales, with a right of first refusal for Sanofi for future commercialization. Initial trials indicated Capeserod's safety and tolerability, and First Wave plans to meet with the FDA to discuss a regulatory pathway for clinical trials starting in 2024. This development is seen as a transformative opportunity for First Wave's pipeline in GI-focused therapies.
Read more →GRDXFirst Wave BioPharma, Inc. Announces Pricing of $2.1 Million Public Offering
First Wave BioPharma, Inc. has announced the pricing of a public offering totaling $2.1 million, involving 3,285,000 shares of common stock and associated warrants. The offering price is set at $0.64 per share, with warrants exercisable immediately and expiring in five years. The funds raised will be used for working capital and general corporate purposes. The completion of the offering is contingent upon customary closing conditions. This action underscores the company's efforts to support its pipeline development in gastrointestinal therapies.
Read more →GRDXFirst Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation
First Wave BioPharma announced initial topline results from its Phase 2 SPAN clinical trial, which focused on an enhanced enteric microgranule formulation of adrulipase for treating exocrine pancreatic insufficiency (EPI) in cystic fibrosis patients. The preliminary results indicate that while the new formulation was safe and well tolerated, it may not have met its primary efficacy endpoint. The company plans to analyze the data further and expects to report more findings in the coming weeks, including discussions with the FDA regarding the next steps for the development process.
Read more →GRDXFirst Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.4 Million Gross Proceeds Priced At-the-Market
First Wave BioPharma has announced the exercise of warrants leading to gross proceeds of approximately $2.4 million. The transaction involves existing warrant holders exercising their warrants at a reduced price of $1.15 per share, in exchange for new warrants. The new warrants, set to expire in five years, will allow the purchase of additional shares. Furthermore, First Wave has agreed to file a resale registration statement with the SEC within 10 days of the transaction's closing.
Read more →GRDXFirst Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
First Wave BioPharma has announced a definitive agreement for a private placement to raise approximately $4 million through the issuance of common stock and warrants. The placement is priced at $3.91 per share, with warrants exercisable at $3.66 per share. The company intends to use the net proceeds for working capital purposes. The transaction is expected to close around March 15, 2023, pending customary closing conditions. First Wave is focused on developing therapies for gastrointestinal diseases, with ongoing clinical programs in this area.
Read more →GRDXFirst Wave BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement Nasdaq Panel Oversight Process Closed
First Wave BioPharma, Inc. has successfully regained compliance with the Nasdaq minimum bid price requirement as of February 6, 2023, and the Nasdaq Hearing Panel has closed its oversight process. This follows the company's previous compliance with the minimum stockholders' equity requirement after a private placement. First Wave BioPharma is currently advancing its clinical pipeline, which includes therapies for gastrointestinal diseases.
Read more →GRDXFirst Wave BioPharma Announces Results of Special Meeting of Stockholders
First Wave BioPharma, Inc. announced that stockholders approved all proposals during its special meeting held on January 13, 2023. Key approvals include the issuance of more than 20% of common stock pursuant to a private placement agreement, and an amendment for a potential reverse stock split. These measures are aimed at fostering future growth as the company continues to develop its pipeline of therapies for gastrointestinal diseases. Results from the special meeting will be documented in a Form 8-K filed with the SEC.
Read more →GRDXFIRST WAVE BIOPHARMA ANNOUNCES DISTRIBUTION OF SERIES F
FIRST WAVE BIOPHARMA ANNOUNCES DISTRIBUTION OF TO HOLDERS OF ITS COMMON BOCA RATON, Fla., November 25, 2022 (GLOBE NEWSWIRE) - First Wave BioPharma, Inc. (NASDAQ: FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the
Read more →GRDXFirst Wave BioPharma, Inc. Announces Private Placement
First Wave BioPharma, Inc. Announces Private BOCA RATON, Fla., November 21, 2022 - First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies
Read more →GRDXFIRST WAVE BIOPHARMA, INC. ANNOUNCES PRICING OF $6.0
WAVE BIOPHARMA, INC. ANNOUNCES PRICING OF $6.0 MILLION PUBLIC OFFERING BOCA RATON, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the develop
Read more →GRDXExbibit 99,1 First Wave BioPharma, Inc. Announces Reverse Stock Split
First Wave BioPharma, Inc. Announces Reverse BOCA RATON, Fla., August 25, 2022 - First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies f
Read more →GRDXFirst Wave BioPharma, Inc. Announces $9 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
First Wave BioPharma, Inc. Announces $9 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules BOCA RATON, Fla., February 28, 2022 - First Wave BioPharma, Inc. (NASDAQ: FWBI) (the "Company"), a clinical stage biopharmaceutical company specializing in the deve
Read more →GRDXFirst Wave BioPharma Chairman and CEO Issues Letter to Shareholders BOCA RATON, FL., December 13 , 2021 (GLOBE NEWSWIRE) - First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders BOCA RATON, FL., December 13, 2021 (GLOBE NEWSWIRE) - First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the develop
Read more →GRDXAzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today Company to begin trading on Nasdaq under new ticker symbol, "FWBI", effective September 22
PRESS RELEASE ANNOUNCING THE NAME CHANGE AND SYMBOL CHANGE, DATED SEPTEMBER 21, 2021 azrx_ex991.htm EXHIBIT 99.1 AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today Company to begin trading on Nasdaq under new ticker symbol, "FWBI", effective September 22
Read more →GRDXAzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
azrx_ex991.htm EXHIBIT 99.1 AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma BOCA RATON, FL., September 14, 2021 (GLOBE NEWSWIRE) - AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("First Wave BioPharm
Read more →GRDXAzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications AzurRx BioPharma to be renamed "First Wave BioPh
azrx_ex991.htm EXHIBIT 99.1 AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications AzurRx BioPharma to be renamed "First Wave BioPharma" and trade under new NASD
Read more →GRDXAzurRx BioPharma Announces Reverse Stock-Split Common Stock Will Begin Trading on Split-Adjusted Basis on
PRESS RELEASE ANNOUNCING THE REVERSE STOCK SPLIT, DATED SEPTEMBER 10, 2021 azrx_ex991.htm EXHIBIT 99.1 AzurRx BioPharma Announces Reverse Stock-Split Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021 BOCA RATON, FL., September 10, 2021 (GLOBE NEWSW
Read more →GRDXAzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI) MS1819 and PERT combination therapy achieves p
azrx_ex991.htm EXHIBIT 99.1 AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI) MS1819 and PERT combination therapy achieves primary and secondary outcome
Read more →GRDXAzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors AzurRx expands Board of Directors to seven members with new appointment
AzurRx BioPharma Announces Appointment of Terry Coelho to its Board AzurRx expands Board of Directors to seven members with new BOCA RATON, Fla., August 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ( AzurRx or the Company ) specializing in the development of targeted n
Read more →GRDXAzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock
AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock RATON, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), ( AzurRx or the Company ), a clinical stage biopharmaceutical company specializing in the development of targete
Read more →GRDXAzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 Clinical Trial Topline Results Conference Call
AzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 Clinical Trial Topline Results Conference Call BEACH, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), ( AzurRx or the Company ), a clinical stage biopharmaceutical company speciali
Read more →GRDXAzurRx BioPharma Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Delray Beach, FL –
AzurRx BioPharma Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Delray Beach, FL March 8, 2021 -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), ( AzurRx or the Company ), a clinical stage biopharmaceutical company specializing in the develo
Read more →GRDXAzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors Former Chairman Edward J. Borkowski to continue as the lead independent director on the board
AzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors Former Chairman Edward J. Borkowski to continue as the lead independent director on the board BEACH, FL., February 24, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASD
Read more →GRDXAzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal I
AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Agreement expands AzurRx's pipeline of targeted, non-syst
Read more →GRDXAzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients Potential to add additional study arm utilizing immediate release capsules Trial objectives, endpoints and sta
AzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients Potential to add additional study arm utilizing immediate release Trial objectives, endpoints and statistical analysis to remain the DELRAY BEACH, Florida, Nov. 17, 2
Read more →GRDXAzurRx BioPharma CEO Issues Clarifying Statement to Shareholders
AzurRx BioPharma CEO Issues Clarifying Statement to NEW YORK, August 12, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ( AzurRx or the Company ) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases,
Read more →GRDXAzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic
AzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency Data from first five patients demonstrate
Read more →GRDXAzurRx BioPharma Closes $15.2 Million Private Placement and $6.9 Million Convertible Note Exchange ● Private placement resulting in gross cash proceeds of $15.2 million to advance two Phase 2 clinical trials of MS
Closes $15.2 Million Private Placement and $6.9 Million Convertible resulting in gross cash proceeds of $15.2 million to advance two Phase 2 clinical trials of MS1819 in patients with cystic million principal amount of outstanding promissory notes into private placement stren
Read more →GRDXAzurRx BioPharma Issues Letter to Shareholders
AzurRx BioPharma Issues Letter to Shareholders YORK, April 21, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ( AzurRx or the Company ) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today issu
Read more →GRDXAzurRx Appoints Gregory Oakes to its Board of Directors Seasoned veteran with decades of strategic and global leadership experience
AzurRx Appoints Gregory Oakes to its Board of Seasoned veteran with decades of strategic and global leadership NEW YORK, April 09, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ( AzurRx or the Company ) a company specializing in the development of non-systemic, recombinant
Read more →GRDXAzurRx BioPharma Receives $1.13 million in 2018 CIR (French Research Tax Credit) ● CIR provides up to 30% in non-dilutive R& D tax relief to eligible research-based French companies ● CIR offers significant
AzurRx BioPharma Receives $1.13 million in 2018 CIR (French Research Tax Credit) CIR provides up to 30% in non-dilutive R& D tax relief to eligible research-based French companies CIR offers significant source of support for on-going MS1819 Phase 2 clinical studies in Europe
Read more →GRDXAzurRx BioPharma Announces Closing of $6.9 Million Private Placement Email
AzurRx BioPharma Announces Closing of $6.9 Million Private NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ( AzurRx or the Company ), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal disease
Read more →GRDXAzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Confer
AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco data from the first f
Read more →GRDXAzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer
AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer YORK, January 3, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) ( AzurRx or the Company ), a company specializing in the development of non-systemic, recombinant therapie
Read more →GRDXAzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund
AzurRx BioPharma, Inc. Announces Equity Purchase for up to $15 Million with Lincoln Park Capital Fund, NEW YORK, November 14, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ( AzurRx or the Company ), a company specializing in the development of non-systemic, r
Read more →GRDXAzurRx BioPharma CEO Issues Letter to Shareholders
AzurRx BioPharma CEO Issues Letter to Shareholders NEW YORK, NY, October 22, 2019 AzurRx BioPharma, Inc. ( AzurRx or the Company ) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today issued the
Read more →GRDXAzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data ● Supports Company plan to proceed to higher 4-gram dose of MS1819-SD in next Phase 2 clinical trial ● No safey concern
AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase Company plan to proceed to higher 4-gram dose of MS1819-SD in next Phase 2 clinical trial concerns cited for MS1819-SD NEW YORK, October 17, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, ( AzurRx or the Company
Read more →GRDXAzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency ● First cystic fibrosis (CF) pati
AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency First cystic fibrosis (CF) patients with severe exocrine pancreatic insufficiency (EPI) treated
Read more →GRDXAzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer Founder and Former CEO Thijs Spoor to Remain on Board of Directors
AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer and Former CEO Thijs Spoor Remain on Board of Directors NEW YORK, October 10, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ( AzurRx or the Company ), a company specializin
Read more →GRDXAzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients Excellent safety results seen in CF patients, with CFA in line with previous studies and no need for a protease Manag
AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis results seen in CF patients, with CFA in line with previous studies and no need for a protease to discuss the results on a call scheduled for today, September 25, 2019 at 8:30 a.m.
Read more →GRDXSECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 to Section 13 or 15(d) of Securities Exchange Act of 1934 Report (Date of earliest event reported): July 17, AZURRX BIOPHARMA, INC. (Exact name of Registrant as specified in its Charter) Delaware 001-37853 46-499386
Read more →GRDXPRESENTATION Untitled Document
PRESENTATION Untitled Document
Read more →GRDXAzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency ● Dose escalation study of
AzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency Dose escalation study of MS1819-SD in combination with standard porcine pancreatic enzyme
Read more →GRDXAzurRx BioPharma Announces Notice of Allowance of U.S. and Japan Patents Covering a MTAN Inhibitor for Treating H. Pylori Infections, the Primary Cause of Stomach Ulcers BROOKLYN, N.Y.
AzurRx BioPharma Announces Notice of Allowance of U.S. and Japan Patents Covering a MTAN Inhibitor for Infections, the Primary Cause of Stomach Ulcers N.Y., June 7, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma Inc. ( AzurRx or the Company ), today announced that both the United
Read more →GRDXADDITIONAL EXHIBITS Untitled Document
ADDITIONAL EXHIBITS Untitled Document
Read more →GRDXAzurRx BioPharma Reaches Enrollment Target for Phase II OPTION Clinical Trial ● Enrollment in AzurRx's Phase II OPTION study has reached target of 30-35 patients ● Screening activities have been completed i
AzurRx BioPharma Reaches Enrollment Target for Phase II OPTION Clinical Trial Enrollment in AzurRx's Phase II OPTION study has reached target of 30-35 patients Screening activities have been completed in AzurRx's Phase II Top-line data expected in Summer 2019 YORK, May 23,
Read more →GRDXAzurRx BioPharma Presents Positive Secondary Endpoint Data in its Phase II MS1819-SD Chronic Pancreatitis Study at the 2019 Digestive Disease Week Conference ● Statistical significance achieved on multiple seconda
BioPharma Presents Positive Secondary Endpoint Data in its Phase II MS1819-SD Chronic Pancreatitis Study at the 2019 Digestive Disease significance achieved on multiple secondary endpoints underscore the potential of MS1819 to provide meaningful clinical benefits to patients
Read more →GRDXAzurRx BioPharma Exceeds 50% Enrollment Target for Phase II OPTION Clinical Trial ● Enrollment in AzurRx's Phase II OPTION study passes 50% enrollment target ● Initial top line data of MS1819-SD in Cystic F
AzurRx BioPharma Exceeds 50% Enrollment Target for Phase II OPTION Enrollment in AzurRx's Phase II OPTION study passes 50% Initial top line data of MS1819-SD in Cystic Fibrosis Patients expected in Summer 2019 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) Com
Read more →GRDXAzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial Initial top line data of MS1819-SD in Cystic Fibrosis Patients expected in mid-2019. ● First patients dosed in open-label, cross-ov
AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Initial top line data of MS1819-SD in Cystic Fibrosis expected in mid-2019. First patients dosed in open-label, cross-over Phase II OPTION study with MS1819-SD for exocrine pancreatic insufficiency in Five cl
Read more →GRDXSecconnect.com AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients First site initiated at the Cystic Fibrosis Institute Initial top line data expected in 2019
AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients First site initiated at the Cystic Fibrosis Institute Initial top line data expected in 2019 NEW YORK, Dec. 19, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NAS
Read more →GRDXAzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group Eliminates milestone and royalty payments to Protea Biosciences Group
AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Eliminates milestone and royalty payments to Protea Biosciences Group NEW YORK, December 12, 2018 -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ( AzurRx or the Company ), a company
Read more →GRDXAzurRx BioPharma to Present at Upcoming Investor Conferences
AzurRx BioPharma to Present at Upcoming Investor December 04, 2018 08:00 ET | Source: AzurRx BioPharma, Inc. BROOKLYN, N.Y., Dec. 04, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, ( AzurRx or the Company ), a company specializing in the development of non-systemic, recombinant
Read more →GRDXCORPORATE PRESENTATION Untitled Document
CORPORATE PRESENTATION Untitled Document
Read more →GRDXSecconnect.com AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPI On t rack to initial Phase 2 trial in cystic fibrosis patients in t
AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPI On track to initial Phase 2 trial in cystic fibrosis patients in the fourth quarter of 2018 and conclude in 2019 NEW YORK, November 1, 2018
Read more →GRDXAzurRx BioPharma Announces FDA Acceptance of IND Application for Phase 2 Clinical Trial of MS1819-SD in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis On track to initiate Phase 2 trial in cystic
AzurRx BioPharma Announces FDA Acceptance of IND Application for Phase 2 Clinical Trial of MS1819-SD in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis On track to initiate Phase 2 trial in cystic fibrosis patients in the fourth quarter of 2018 and conc
Read more →GRDXAzurRx BioPharma Announces Positive Outcome with MS1819-SD Showing Statistically Significant Efficacy in a Phase IIa Exocrine Pancreatic Insufficiency Trial in Chronic Pancreatitis Data reaffirms positive safety profile
AzurRx BioPharma Announces Positive Outcome with MS1819-SD Showing Statistically Significant Efficacy in a Phase IIa Exocrine Pancreatic Insufficiency Trial in Chronic Pancreatitis Data reaffirms positive safety profile with no severe adverse events NEW YORK, September 24, 2018
Read more →GRDXAzurRx BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference on September 5th BROOKLYN, N.Y.
AzurRx BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference on September 5th N.Y., Aug. 28, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ( AzurRx or the Company ), a company specializing in the development of non-systemic, recombinant ther
Read more →GRDXBlueprint AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency
AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency NEW YORK, June 29, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ( AzurRx or the Company ), a company specializing in the development of non-systemic, rec
Read more →GRDXAzurRx Announces Appointment of Dr. James Pennington as Chief Medical Officer
AzurRx Announces Appointment of Dr. James Pennington as Chief NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ( AzurRx or the Company ), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal dise
Read more →GRDXAzurRx BioPharma Announces Proposed Public Offering of Common Stock Brooklyn, NY - (GLOBE NEWSWIRE)
AzurRx BioPharma Announces Proposed Public Offering of Common Stock NY - (GLOBE NEWSWIRE) April 30, 2018 AzurRx BioPharma (NASDAQ: AZRX), ( AzurRx or the Company ), announced today that it intends to offer and sell shares of its common stock in an underwritten public offeri
Read more →GRDXAzurRx BioPharma and Mayoly-Spindler Announce Additional Positive Interim Data for MS1819-SD Phase II in Exocrine Pancreatic Insufficiency (EPI) BROOKLYN, N.Y.
AzurRx BioPharma and Mayoly-Spindler Announce Additional Positive Interim Data for MS1819-SD Phase II in Exocrine Pancreatic BROOKLYN, N.Y., April 23, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma Inc. (NASDAQ:AZRX) ( AzurRx or the Company ), today provided an update on the firs
Read more →GRDXAzurRx BioPharma Announces Positive Preclinical Data with AZX1103 ● Company is developing AZX1103 for the prevention of nosocomial infections induced by administration of several classes of antibiotics ● AZ
AzurRx BioPharma Announces Positive Preclinical Data with is developing AZX1103 for the prevention of nosocomial infections induced by administration of several classes of shown to be safe and biologically active in a well-established Brooklyn, NY (GLOBE NEWSWIRE) April 18, 2
Read more →GRDXAzurRx BioPharma to Present at the Biotech Showcase 2018 Conference (January 8th) BROOKLYN, N.Y.
AzurRx BioPharma to Present at the Biotech Showcase 2018 Conference BROOKLYN, N.Y., Dec. 04, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, ( AzurRx or the Company ), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, a
Read more →GRDXAzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI) Brooklyn, NY – (GLOBE NEWSWIRE)
AzurRx BioPharma and Mayoly-Spindler Positive MS1819-SD Phase II Data in Exocrine Pancreatic (GLOBE NEWSWIRE) September 27, 2017 ( AzurRx or the Company ), today provided an update on the first six treated patients in its ongoing Phase IIa trial of MS1819-SD, a recombinant l
Read more →GRDXAzurRx BioPharma Announces Closing of $5.0 Million Private Financing BROOKLYN, N.Y.
AzurRx BioPharma Announces Closing of $5.0 Million Private BROOKLYN, N.Y., June 8, 2017. (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc.(NASDAQ:AZRX) ( AzurRx or the Company ), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal d
Read more →GRDXAzurRx Provides Update on MS1819 Phase II Trial Initial patient experience shows no safety issues MS1819 appears active, as demonstrated by CFA increases 20% at various dosing levels BROOKLYN, N.Y.
AzurRx Provides Update on MS1819 Phase II Trial Initial patient experience shows no safety issues MS1819 appears active, as demonstrated by CFA increases >20% at various dosing levels N.Y., April 11, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ( AzurRx or the Company ),
Read more →GRDXAzurRx Announces Addition of Charles J Casamento to the Board of Directors
Addition of Charles J Casamento to the Board of YORK, March 08, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ( AzurRx or the Company ) a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases today announced the appoin
Read more →GRDXAzurRx BioPharma Martin Krusin –Vice President Phone: + 1 646-699-7855 Email:mkrusin@azurrx.com AzurRx BioPharma Announces Pricing of Initial Public Offering Brooklyn, NY –
Email:mkrusin@azurrx.com BioPharma Announces Pricing of Initial Public October 11, 2016 AzurRx BioPharma Inc. (NASDAQ: AZRX) ( AzurRx or the Company ), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced t
Read more →Competitive Position
How GRDX ranks across every disease it competes inCompetitive Position is a premium feature
See how GRDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial